We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Eli Lilly already has a couple of top GLP-1 drugs that help patients with diabetes (Mounjaro) and weight loss (Zepbound), but ...

Amid the tragedy of the Israel-Iran conflict, stocks are proving stoic. Futures early Monday, as the missile attacks continued, showed the S&P 500 once again reclaiming the 6,000 mark. That's only ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Novo Nordisk's shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe's largest by market capitalization. Novo Nordisk's ADR (NVO) (DK:NOVO.B), at ...

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from ...

The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners.

The current health news highlights a series of dynamic events, including Parvus Asset Management's stake in Novo Nordisk, WHO ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below. The ...